{"entity": "researcher", "timestamp": "2026-08-22T06:56:03.531Z", "family": "Kvitne", "given": "Kine Eide", "initials": "KE", "orcid": "0000-0001-8118-7660", "affiliations": ["Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/2cc96a6df2d34cf7a41eb1fd7ba2887e.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/2cc96a6df2d34cf7a41eb1fd7ba2887e"}}, "publications": [{"entity": "publication", "iuid": "c743b2a3a4ad40899df9fadab69453ce", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c743b2a3a4ad40899df9fadab69453ce.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c743b2a3a4ad40899df9fadab69453ce"}}, "title": "Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.", "authors": [{"family": "Kvitne", "given": "Kine Eide", "initials": "KE", "orcid": "0000-0001-8118-7660", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2cc96a6df2d34cf7a41eb1fd7ba2887e.json"}}, {"family": "\u00c5sberg", "given": "Anders", "initials": "A", "orcid": "0000-0002-0628-1769", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/153c90f914b4461b8fa381a2e24a7954.json"}}, {"family": "Johnson", "given": "Line K", "initials": "LK"}, {"family": "Wegler", "given": "Christine", "initials": "C"}, {"family": "Hertel", "given": "Jens K", "initials": "JK"}, {"family": "Artursson", "given": "Per", "initials": "P", "orcid": "0000-0002-3708-7395", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9908209a413a4088b6bf44a924d27319.json"}}, {"family": "Karlsson", "given": "Cecilia", "initials": "C", "orcid": "0000-0002-4299-8775", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e8e4f9bc85a4912bc72bf0430c1360b.json"}}, {"family": "Andersson", "given": "Shalini", "initials": "S"}, {"family": "Sandbu", "given": "Rune", "initials": "R"}, {"family": "Skovlund", "given": "Eva", "initials": "E"}, {"family": "Christensen", "given": "Hege", "initials": "H"}, {"family": "Jansson-L\u00f6fmark", "given": "Rasmus", "initials": "R"}, {"family": "Hjelmesaeth", "given": "J\u00f8ran", "initials": "J"}, {"family": "Robertsen", "given": "Ida", "initials": "I"}], "type": "journal article", "published": "2022-11-00", "journal": {"title": "Clin Transl Sci", "issn": "1752-8062", "volume": "15", "issue": "11", "pages": "2685-2696", "issn-l": null}, "abstract": "Previous studies have not accounted for the close link between type 2 diabetes mellitus (T2DM) and obesity when investigating the impact of T2DM on cytochrome P450 (CYP) activities. The aim was to investigate the effect of T2DM on in vivo activities and protein expressions of CYP2C19, CYP3A, CYP1A2, and CYP2C9 in patients with obesity. A total of 99 patients from the COCKTAIL study (NCT02386917) were included in this cross-sectional analysis; 29 with T2DM and obesity (T2DM-obesity), 53 with obesity without T2DM (obesity), and 17 controls without T2DM and obesity (controls). CYP activities were assessed after the administration of a cocktail of probe drugs including omeprazole (CYP2C19), midazolam (CYP3A), caffeine (CYP1A2), and losartan (CYP2C9). Jejunal and liver biopsies were also obtained to determine protein concentrations of the respective CYPs. CYP2C19 activity and jejunal CYP2C19 concentration were 63% (-0.39 [95% CI: -0.82, -0.09]) and 40% (-0.09 fmol/\u03bcg protein [95% CI: -0.18, -0.003]) lower in T2DM-obesity compared with the obesity group, respectively. By contrast, there were no differences in the in vivo activities and protein concentrations of CYP3A, CYP1A2, and CYP2C9. Multivariable regression analyses also indicated that T2DM was associated with interindividual variability in CYP2C19 activity, but not CYP3A, CYP1A2, and CYP2C9 activities. The findings indicate that T2DM has a significant downregulating impact on CYP2C19 activity, but not on CYP3A, CYP1A2, and CYP2C9 activities and protein concentrations in patients with obesity. Hence, the effect of T2DM seems to be isoform-specific.", "doi": "10.1111/cts.13394", "pmid": "36037309", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9652437"}, {"db": "ClinicalTrials.gov", "key": "NCT02386917"}], "notes": [], "created": "2026-08-21T12:18:17.769Z", "modified": "2026-08-21T12:18:17.855Z"}, {"entity": "publication", "iuid": "efabd2364eb647cebc5a8550720e040b", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/efabd2364eb647cebc5a8550720e040b.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/efabd2364eb647cebc5a8550720e040b"}}, "title": "Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity.", "authors": [{"family": "Kvitne", "given": "Kine Eide", "initials": "KE", "orcid": "0000-0001-8118-7660", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2cc96a6df2d34cf7a41eb1fd7ba2887e.json"}}, {"family": "Krogstad", "given": "Veronica", "initials": "V"}, {"family": "Wegler", "given": "Christine", "initials": "C", "orcid": "0000-0002-2810-7518", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fcb45d19c52847f19bd5c0aa296afe10.json"}}, {"family": "Johnson", "given": "Line Kristin", "initials": "LK"}, {"family": "Kringen", "given": "Marianne K", "initials": "MK"}, {"family": "Hovd", "given": "Markus Herberg", "initials": "MH", "orcid": "0000-0002-6077-0934", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/40bec1eda0684e43a25fb3a9552d9f03.json"}}, {"family": "Hertel", "given": "Jens K", "initials": "JK"}, {"family": "Heijer", "given": "Maria", "initials": "M"}, {"family": "Sandbu", "given": "Rune", "initials": "R"}, {"family": "Skovlund", "given": "Eva", "initials": "E"}, {"family": "Artursson", "given": "Per", "initials": "P"}, {"family": "Karlsson", "given": "Cecilia", "initials": "C"}, {"family": "Andersson", "given": "Shalini", "initials": "S"}, {"family": "Andersson", "given": "Tommy B", "initials": "TB"}, {"family": "Hjelmesaeth", "given": "J\u00f8ran", "initials": "J"}, {"family": "\u00c5sberg", "given": "Anders", "initials": "A", "orcid": "0000-0002-0628-1769", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/153c90f914b4461b8fa381a2e24a7954.json"}}, {"family": "Jansson-L\u00f6fmark", "given": "Rasmus", "initials": "R"}, {"family": "Christensen", "given": "Hege", "initials": "H"}, {"family": "Robertsen", "given": "Ida", "initials": "I", "orcid": "0000-0001-9401-7716", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fbbacb93696b4b42b4796fc8a3dab7b2.json"}}], "type": "clinical trial", "published": "2022-09-00", "journal": {"title": "Br J Clin Pharmacol", "issn": "1365-2125", "volume": "88", "issue": "9", "pages": "4121-4133", "issn-l": null}, "abstract": "Roux-en-Y gastric bypass (RYGB) may influence drug disposition due to surgery-induced gastrointestinal alterations and/or subsequent weight loss. The objective was to compare short- and long-term effects of RYGB and diet on the metabolic ratios of paraxanthine/caffeine (cytochrome P450 [CYP] 1A2 activity), 5-hydroxyomeprazole/omeprazole (CYP2C19 activity) and losartan/losartan carboxylic acid (CYP2C9 activity), and cross-sectionally compare these CYP-activities with normal-to-overweight controls.\n\nThis trial included patients with severe obesity preparing for RYGB (n = 40) or diet-induced (n = 41) weight loss, and controls (n = 18). Both weight loss groups underwent a 3-week low-energy diet (<1200 kcal/day, weeks 0-3) followed by a 6-week very-low-energy diet or RYGB (both <800 kcal/day, weeks 3-9). Follow-up time was 2 years, with four pharmacokinetic investigations.\n\nMean \u00b1 SD weight loss from baseline was similar in the RYGB-group (13 \u00b1 2.4%) and the diet group (10.5 \u00b1 3.9%) at week 9, but differed at year 2 (RYGB -30 \u00b1 6.9%, diet -3.1 \u00b1 6.3%). From weeks 0 to 3, mean (95% confidence interval [CI]) CYP2C19 activity similarly increased in both groups (RYGB 43% [16, 55], diet 48% [22, 60]). Mean CYP2C19 activity increased by 30% (2.6, 43) after RYGB (weeks 3-9), but not in the diet-group (between-group difference -0.30 [-0.63, 0.03]). CYP2C19 activity remained elevated in the RYGB group at year 2. Baseline CYP2C19 activity was 2.7-fold higher in controls compared with patients with obesity, whereas no difference was observed in CYP1A2 and CYP2C9 activities.\n\nOur findings suggest that CYP2C19 activity is lower in patients with obesity and increases following weight loss. This may be clinically relevant for drug dosing. No clinically significant effect on CYP1A2 and CYP2C9 activities was observed.", "doi": "10.1111/bcp.15349", "pmid": "35404513", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9541356"}], "notes": [], "created": "2026-08-21T12:17:28.245Z", "modified": "2026-08-21T12:17:28.434Z"}]}